A Phase 2, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease

被引：2
|
作者：
Andemariam, Biree [1 ]
Sheehan, Vivien A. [2 ]
Hamza, Moayed [3 ]
Kelly, Kirsty [3 ]
Climax, John [3 ]
机构：
[1] Univ Connecticut Hlth, Farmington, CT USA
[2] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[3] Afimmune, Dublin, Ireland
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188727
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease
    Kanter, Julie
    Elliott, Brian
    Weber, Denis
    Tanaka, Chiaki
    Xiang, Fang
    Ataga, Kenneth I.
    BLOOD, 2017, 130
  • [2] A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington's Disease (HD)
    Kumar, Rajeev
    Claassen, Daniel
    Mongan, Ann
    Hoehn, Benjamin
    Lin, Ping
    Cahir-Mcfarland, Ellen
    Guo, Chenying
    Volman, Vladislav
    Taylor, Lori
    Chandra, Priya
    Yednock, Ted
    Kroon, Henk-Andre
    NEUROLOGY, 2023, 100 (17)
  • [3] An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
    Li, Jia
    Rockich, Kevin
    Yuska, Brad
    Zhou, Gongfu
    Epstein, Noam
    Punwani, Naresh
    Chen, Xuejun
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (11): : 1519 - 1526
  • [4] Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
    Zhang, Jing
    Wan, Weiguo
    Miao, Liyan
    Wu, Jian
    Dong, Jun
    Shen, Yinghua
    Xiong, Cui
    Li, Chao
    Xue, Yu
    Cao, Guoying
    Ma, Peiming
    RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 191 - 200
  • [5] Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
    Jing Zhang
    Weiguo Wan
    Liyan Miao
    Jian Wu
    Jun Dong
    Yinghua Shen
    Cui Xiong
    Chao Li
    Yu Xue
    Guoying Cao
    Peiming Ma
    Rheumatology and Therapy, 2020, 7 : 191 - 200
  • [6] Pharmacokinetics, Pharmacodynamics, and Safety of Pasireotide LAR in Patients With Acromegaly: A Randomized, Multicenter, Open-Label, Phase I Study
    Petersenn, Stephan
    Bollerslev, Jens
    Arafat, Ayman M.
    Schopohl, Jochen
    Serri, Omar
    Katznelson, Laurence
    Lasher, Janet
    Hughes, Gareth
    Hu, Ke
    Shen, George
    Resendiz, Karina Hermosillo
    Giannone, Vanessa
    Beckers, Albert
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11): : 1308 - 1317
  • [7] Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study
    Watanabe, Eizo
    Nishida, Osamu
    Kakihana, Yasuyuki
    Odani, Motoi
    Okamura, Tatsuaki
    Harada, Tomohiro
    Oda, Shigeto
    SHOCK, 2020, 53 (06): : 686 - 694
  • [8] Phase II open-label, safety, pharmacolkinetic and efficacy study of Panzem® NCD administered orally to patients with ovarian cancer
    Matei, Daniela
    Schilder, Jeanne
    Menning, Nancy
    Arnott, Jamie
    Sutton, Gregory
    Koneru, Karuna
    Sidor, Carolyn
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3339S - 3339S
  • [9] Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study
    van Dijk, Myrthe J.
    Rab, Minke A. E.
    van Oirschot, Brigitte A.
    Bos, Jennifer
    Derichs, Cleo
    Rijneveld, Anita W.
    Cnossen, Marjon H.
    Nur, Erfan
    Biemond, Bart J.
    Bartels, Marije
    Jans, Judith J. M.
    van Solinge, Wouter W.
    Schutgens, Roger E. G.
    van Wijk, Richard
    van Beers, Eduard J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (07) : E226 - E229
  • [10] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
    Howard, Jo
    Hemmaway, Claire Jane
    Telfer, Paul
    Layton, D. Mark
    Porter, John
    Awogbade, Moji
    Mant, Timothy
    Gretler, Daniel D.
    Dufu, Kobina
    Hutchaleelaha, Athiwat
    Patel, Mira
    Siu, Vincent
    Dixon, Sandra
    Landsman, Noel
    Tonda, Margaret
    Lehrer-Graiwer, Joshua
    BLOOD, 2019, 133 (17) : 1865 - 1875
12345